metamfetamine

N06BA03

Forms & Strengths

Adult Dosing

Attention Deficit Hyperactivity Disorder (ADHD): 5 mg orally once or twice daily, titrated at weekly intervals up to 20-25 mg/daily.
Exogenous Obesity: 5 mg orally before each meal, or a single 10-15 mg long-acting dose in the morning for short-term use.

Pediatric Dosing

ADHD (Patients 6 years and older): 5 mg orally once or twice daily, titrated at weekly intervals by 5 mg increments to a usual effective dose of 20-25 mg daily.

Indications

Mechanism of Action

Sympathomimetic amine with CNS stimulant activity; promotes release of dopamine and other monoamines from nerve terminals in the brain and inhibits their reuptake.

Contraindications

Known hypersensitivity to sympathomimetic amines
History of cardiovascular disease (e.g., advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension)
Glaucoma
Hyperthyroidism
Agitated states
History of drug abuse
Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing them

Adverse Reactions

Cardiovascular: Hypertension, tachycardia, palpitations, arrhythmia, angina, ischemic events
Central Nervous System: Insomnia, nervousness, jitteriness, euphoria, psychosis, tremor
Gastrointestinal: Dry mouth, nausea, vomiting, diarrhea, constipation, anorexia, weight loss
Psychiatric: Dependence, tolerance, abuse potential, withdrawal symptoms

Drug Interactions

Monoamine oxidase inhibitors (MAOIs): Risk of severe hypertensive crisis
CYP2D6 inhibitors: May increase plasma concentrations of methamphetamine
Antihypertensive drugs: Efficacy may be antagonized by sympathomimetics
Acidifying agents (e.g., ascorbic acid, ammonium chloride): Increase urinary excretion and decrease blood levels of methamphetamine
Alkalinizing agents (e.g., sodium bicarbonate): Decrease urinary excretion and increase blood levels of methamphetamine

Curated Content: Needs Vetting Before Put to Clinical Use